Malini Reddy, MD
Internal Medicine · Athens, GANPI 1568705135
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 32.3% of the total. Reporting peaked in 2024 at $628 and has fallen 65.9% since, to $215 in 2025.
Across 166 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$873
- Amgen$305
- GSK$267
- Lilly USA, LLC$173
- AstraZeneca$158
- Sanofi-aventis U.S. LLC$99
- plus $828 from 19 others
What the payments were for
- Food & beverage$2,704100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $873 |
| Amgen | 18 | $305 |
| GSK | 17 | $267 |
| Lilly USA, LLC | 11 | $173 |
| AstraZeneca | 11 | $158 |
| Sanofi-aventis U.S. LLC | 6 | $99 |
| Novo Nordisk | 6 | $94 |
| Amarin Pharma, Inc. | 5 | $91 |
| Pfizer | 5 | $76 |
| Dexcom, Inc. | 3 | $64 |
| Astellas Pharma US Inc | 3 | $55 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Philips North America LLC | 3 | $50 |
| Exact Sciences | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Merck | 3 | $43 |
| Abbott | 2 | $43 |
| Shire North American Group Inc | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Saluda Medical Americas, Inc. | 1 | $25 |
| Optos, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Linus Health, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$2,704 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $49,103 |
| OzempicSemaglutide | 35 | $44,913 |
| FarxigaDapagliflozin Propanediol | 49 | $40,532 |
| EliquisApixaban | 29 | $35,608 |
| JardianceEmpagliflozin | 26 | $30,613 |
| TrintellixVortioxetine Hydrobromide | 13 | $12,136 |
| MyrbetriqMirabegron | 11 | $11,842 |
| XareltoRivaroxaban | 12 | $9,879 |
| LinzessLinaclotide | 11 | $8,304 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $2,298 |
| Atorvastatin Calcium | 286 | $2,222 |
| Bupropion XlBupropion Hcl | 27 | $1,968 |
| Azelastine Hcl | 33 | $1,689 |
| Omeprazole | 124 | $1,659 |
| Gabapentin | 87 | $1,565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $267 | $49,10338 claims |
| Novo NordiskOzempic | $94 | $44,91335 claims |
| AstraZenecaFarxiga | $158 | $40,53249 claims |
| PfizerEliquis | $76 | $35,60829 claims |
| Boehringer IngelheimJardiance | $13 | $30,61326 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $44 | $12,13613 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $11,84211 claims |
| AbbVieLinzess | $873 | $8,30411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Athens
- Asif QadriAthens$18K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.